Domenica Lorusso

37.7k total citations · 6 hit papers
521 papers, 9.7k citations indexed

About

Domenica Lorusso is a scholar working on Reproductive Medicine, Oncology and Obstetrics and Gynecology. According to data from OpenAlex, Domenica Lorusso has authored 521 papers receiving a total of 9.7k indexed citations (citations by other indexed papers that have themselves been cited), including 320 papers in Reproductive Medicine, 249 papers in Oncology and 197 papers in Obstetrics and Gynecology. Recurrent topics in Domenica Lorusso's work include Ovarian cancer diagnosis and treatment (300 papers), Endometrial and Cervical Cancer Treatments (187 papers) and PARP inhibition in cancer therapy (117 papers). Domenica Lorusso is often cited by papers focused on Ovarian cancer diagnosis and treatment (300 papers), Endometrial and Cervical Cancer Treatments (187 papers) and PARP inhibition in cancer therapy (117 papers). Domenica Lorusso collaborates with scholars based in Italy, United States and Spain. Domenica Lorusso's co-authors include Giovanni Scambia, Francesco Raspagliesi, Nicoletta Colombo, Gabriella Ferrandina, Antonino Ditto, Giorgio Bogani, Fabio Martinelli, Ana Oaknin, Sandro Pignata and Philipp Harter and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Domenica Lorusso

487 papers receiving 9.6k citations

Hit Papers

Pembrolizumab for Persistent, Recurrent, or Metastatic Ce... 2021 2026 2022 2024 2021 2022 2023 2021 2023 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
    2021 581 citations Nicoletta Colombo, Coraline Dubot et al. profile →
  2. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    2022 304 citations Ana Oaknin, Philipp Harter et al. profile →
  3. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
    2023 220 citations Ursula A. Matulonis, Domenica Lorusso et al. Journal of Clinical Oncology profile →
  4. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
    2021 186 citations Kathleen N. Moore, Amit M. Oza et al. profile →
  5. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    2023 149 citations Philipp Harter, Alexandra Léary et al. profile →
  6. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826
    2023 100 citations Bradley J. Monk, Nicoletta Colombo et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Domenica Lorusso Italy 46 4.9k 3.6k 3.3k 2.6k 1.5k 521 9.7k
John K. Chan United States 60 5.1k 1.1× 4.1k 1.1× 3.7k 1.1× 2.9k 1.1× 1.9k 1.3× 277 11.9k
Helen Huang United States 30 4.8k 1.0× 2.9k 0.8× 2.6k 0.8× 2.7k 1.0× 1.3k 0.9× 68 8.1k
Angiolo Gadducci Italy 55 5.0k 1.0× 2.3k 0.6× 3.9k 1.2× 2.3k 0.9× 1.7k 1.1× 374 9.6k
Sandro Pignata Italy 51 4.2k 0.9× 4.4k 1.2× 2.0k 0.6× 2.4k 0.9× 2.4k 1.6× 434 10.6k
Francesco Raspagliesi Italy 46 4.1k 0.8× 1.9k 0.5× 4.1k 1.2× 2.2k 0.8× 1.0k 0.7× 394 8.2k
Sërgio Pecorelli Italy 50 4.2k 0.9× 2.9k 0.8× 3.9k 1.2× 2.1k 0.8× 2.1k 1.4× 178 10.6k
Thomas J. Herzog United States 64 6.2k 1.3× 3.2k 0.9× 6.1k 1.8× 3.3k 1.3× 1.8k 1.2× 334 13.3k
Peter G. Rose United States 54 5.8k 1.2× 3.2k 0.9× 6.5k 1.9× 4.1k 1.6× 1.6k 1.1× 274 12.2k
Angeles Alvarez Secord United States 46 3.6k 0.7× 2.3k 0.6× 3.0k 0.9× 1.1k 0.4× 1.5k 1.0× 288 7.2k
Benjamin E. Greer United States 40 5.6k 1.1× 2.7k 0.7× 2.9k 0.9× 2.4k 0.9× 1.5k 1.0× 115 8.8k

Countries citing papers authored by Domenica Lorusso

Since Specialization
Citations

This map shows the geographic impact of Domenica Lorusso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Domenica Lorusso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Domenica Lorusso more than expected).

Fields of papers citing papers by Domenica Lorusso

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Domenica Lorusso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Domenica Lorusso. The network helps show where Domenica Lorusso may publish in the future.

Co-authorship network of co-authors of Domenica Lorusso

This figure shows the co-authorship network connecting the top 25 collaborators of Domenica Lorusso. A scholar is included among the top collaborators of Domenica Lorusso based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Domenica Lorusso. Domenica Lorusso is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Marchetti, Cláudia, Diana Giannarelli, Francesco Pepe, et al.. (2025). Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery. Gynecologic Oncology. 195. 16–25. 1 indexed citations
2.
Lorusso, Domenica, et al.. (2024). Venous Thromboembolism Prophylaxis in Gynecologic Oncology: A MITO-MaNGO Survey. Diagnostics. 14(11). 1159–1159. 1 indexed citations
3.
McCormack, Mary, Yong‐Man Kim, Sharad Ghamande, et al.. (2024). A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04). International Journal of Gynecological Cancer. 34(8). 1140–1148. 16 indexed citations
4.
You, Benoît, Anna Fagotti, Olivier Colomban, et al.. (2024). Consistent data about the predictive factors of the success of interval debulking surgery (CC0-IDS) in patients with advanced ovarian cancers in two large independent datasets.. Journal of Clinical Oncology. 42(16_suppl). 5560–5560.
5.
Fagotti, Anna, Chiara Cassani, Lorena Incorvaia, et al.. (2023). 42P Efficacy of maintenance with PARPi in advanced ovarian cancer according to the location of BRCA mutation. ESMO Open. 8(1). 100822–100822. 1 indexed citations
6.
Monk, Bradley J., Nicoletta Colombo, Krishnansu S. Tewari, et al.. (2023). First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826. Journal of Clinical Oncology. 41(36). 5505–5511. 100 indexed citations breakdown →
7.
Vergote, Ignace, Isabelle Ray‐Coquard, Domenica Lorusso, et al.. (2023). Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?. Expert Opinion on Investigational Drugs. 32(3). 201–211. 5 indexed citations
8.
Capasso, Ilaria, Angela Santoro, Emanuela Lucci‐Cordisco, et al.. (2023). Lynch Syndrome and Gynecologic Tumors: Incidence, Prophylaxis, and Management of Patients with Cancer. Cancers. 15(5). 1400–1400. 14 indexed citations
9.
Kacperczyk‐Bartnik, Joanna, Nicolò Bizzarri, Martina Aida Ángeles, et al.. (2023). Best original research presented at the 24th European Congress on Gynaecological Oncology—Best of ESGO 2023. International Journal of Gynecological Cancer. 34(4). 610–618. 1 indexed citations
10.
11.
Lorusso, Domenica, Vicky Makker, Antonio Casado, et al.. (2022). 2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775. International Journal of Gynecological Cancer. 32. A102–A102. 1 indexed citations
12.
Coleman, Robert L., Amit M. Oza, Domenica Lorusso, et al.. (2022). 2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. International Journal of Gynecological Cancer. 32. A226–A226. 16 indexed citations
13.
14.
15.
Bartoletti, Michele, Alice Bergamini, Gaia Giannone, et al.. (2022). A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group. International Journal of Gynecological Cancer. 32(9). 1205–1207. 4 indexed citations
16.
Falandry, Claire, Fanny Pommeret, Laurence Gladieff, et al.. (2022). Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study. The Lancet Healthy Longevity. 3(3). e176–e185. 7 indexed citations
17.
Bizzarri, Nicolò, Camilla Nero, Francesca Ciccarone, et al.. (2021). Building a Personalized Medicine Infrastructure for Gynecological Oncology Patients in a High-Volume Hospital. Journal of Personalized Medicine. 12(1). 3–3. 4 indexed citations
18.
Pietragalla, Antonella, Simona Duranti, Gennaro Daniele, et al.. (2021). Oregovomab: an investigational agent for the treatment of advanced ovarian cancer. Expert Opinion on Investigational Drugs. 30(2). 103–110. 8 indexed citations
19.
Giudice, Elena, Vanda Salutari, Caterina Ricci, et al.. (2021). Gut microbiota and its influence on ovarian cancer carcinogenesis, anticancer therapy and surgical treatment: A literature review. Critical Reviews in Oncology/Hematology. 168. 103542–103542. 8 indexed citations
20.
Maltese, Giuseppa, Caterina Fontanella, Cono Scaffa, et al.. (2017). Atypical Uterine Smooth Muscle Tumors: A Retrospective Evaluation of Clinical and Pathologic Features. Oncology. 94(1). 1–6. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John K. Chan Breakdown of academic impact, for papers by Helen Huang Breakdown of academic impact, for papers by Angiolo Gadducci Breakdown of academic impact, for papers by Sandro Pignata Breakdown of academic impact, for papers by Francesco Raspagliesi Breakdown of academic impact, for papers by Sërgio Pecorelli Breakdown of academic impact, for papers by Thomas J. Herzog Breakdown of academic impact, for papers by Peter G. Rose Breakdown of academic impact, for papers by Angeles Alvarez Secord Breakdown of academic impact, for papers by Benjamin E. Greer
Rankless by CCL
2026